Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 65.50% from the company’s previous close.

A number of other brokerages have also commented on ORKA. Stifel Nicolaus started coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Lifesci Capital initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Wedbush initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Down 2.9 %

Oruka Therapeutics stock opened at $27.19 on Thursday. The firm has a market cap of $32.85 million, a price-to-earnings ratio of -4.53 and a beta of 0.89. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88. The business’s 50 day moving average is $26.86.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. On average, sell-side analysts anticipate that Oruka Therapeutics will post -1.69 earnings per share for the current year.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.